Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caffeine in Neonates With Hypoxic-Ischemic Encephalopathy
NCT06448780Phase 1Active, not recruiting
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Jul 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of caffeine in hypoxic-ischemic encephalopathy (HIE) (2 arms), sponsored by University of North Carolina at Chapel Hill. Primary endpoints: Apparent Caffeine Clearance and Volume of Distribution of Caffeine. Started Jul 2024; status: active, not recruiting.
02
Drugs
caffeine
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on NCT06448780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06448780.